Koyfin Home > Directory > Health Care > Gilead Sciences Inc > Long-Term Debt

Gilead Sciences Inc Long-Term Debt Chart (GILD)

Gilead Sciences Inc annual/quarterly Long-Term Debt from 2010 to 2020.
  • Gilead Sciences Inc Long-Term Debt for the quarter ending June 06, 2020 was $21,103m a -4.68% decrease of -987m year over year
  • Gilead Sciences Inc Long-Term Debt for the last 12 months ending June 06, 2020 was $21,103m a -4.68% decrease of -987m year over year
  • Gilead Sciences Inc Annual Long-Term Debt for 2019 was $22,094m a -11.22% decrease of -2,480m from 2018
  • Gilead Sciences Inc Annual Long-Term Debt for 2018 was $24,574m a -25.32% decrease of -6,221m from 2017
  • Gilead Sciences Inc Annual Long-Term Debt for 2017 was $30,795m a 14.45% increase of 4,449m from 2016
Other Cash Flow Metrics:
  • Gilead Sciences Inc Cash Flow from Operations for the quarter ending September 09, 2018 was $2,212m a -24.46% decrease of -541m year over year
  • Gilead Sciences Inc Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $1,592m a -123.19% decrease of -1,962m year over year
  • Gilead Sciences Inc Total Revenue for the quarter ending December 12, 2018 was $5,795m a 12.20% increase of 707m year over year
View Chart On Koyfin

Quarterly GILD Long-Term Debt Data

06/2020$21,103m
03/2020$22,098m
12/2019$22,094m
09/2019$22,090m
06/2019$24,084m
03/2019$24,080m
12/2018$24,574m
09/2018$24,570m
06/2018$26,062m
03/2018$26,557m

Annual GILD Long-Term Debt Data

2019$22,094m
2018$24,574m
2017$30,795m
2016$26,346m
2015$21,073m
2014$11,921m
2013$3,939m
2012$7,055m
2011$7,606m
2010$2,839m